Hints and tips:
Showing results for PAR Pharmaceutical Companies Inc
Related Special Reports
...WPP’s Ogilvy advertising agency is creating a division specialising in online “health influencers” to help pharmaceutical companies tap a trend towards personalised health and combat misinformation....
...A Humira biosimilar from Teva Pharmaceuticals working with Alvotech earlier this year became the first drug that the US Food and Drug Administration granted interchangeable status, which lets pharmacists...
...Panuwat’s company, Medivation, was bought in 2016 by Pfizer for $14bn. But the stock he purchased at the time was not that of Medivation....
...The case is the latest in a series of intellectual property battles that companies are fighting around the world over mRNA technology, which has helped generate billions in revenues for the pharmaceuticals...
...Any rumours that the company is at risk of defaulting are “flatly untrue”, he said....
...“The biggest barrier is insurance companies,” said Lawrence Honig, a neurologist at New York’s Columbia University Irving Medical Center....
...Shockwave’s technology has treated approximately 400,000 patients globally, the company said....
...Obviously, this flavour of defence is par for the course in antitrust, but we were curious whether Crevoiserat has been serving a similarly smol bean line to investors....
...Shah Capital now owns 6.7 per cent of Novavax, having first bought into the company in the last quarter of 2022....
...Illumina said the company agreed “with the advocate general that the European Commission’s assertion of jurisdiction over this merger was improper”. Illumina bought Grail in 2021....
...The company said the security services were “in the interests of the company and its shareholders”, owing to the “critical value” the pair provided....
...Avid Bioservices, a small-cap company that helps develop and manufacture drugs for pharmaceutical companies, filed this with the SEC yesterday: On February 29, 2024, Avid Bioservices, Inc....
...Then, GLP-1 anti-obesity drugs hit the market, long-time spokesperson and board member Oprah Winfrey announced her departure, and the company’s credit rating was downgraded....
...Among the surprises: the company’s investments in bitcoin and ether and the inclusion of entities affiliated with OpenAI’s Sam Altman, Silicon Valley networker par excellence, among the biggest investors...
...The Medicines and Healthcare products Regulatory Agency has approved the therapy, called Casgevy, which was developed by Vertex Pharmaceuticals and Crispr Therapeutics....
...Despite splashing out nearly $55bn on two major acquisitions over the past two years, the pharmaceutical company is worth less than it was before the pandemic....
...The company may have missed out on the early flush of AI hype but it has also avoided rushing out a sub-par product that might harm its reputation....
...Pfizer shares tumbled more than 8 per cent after the US drugmaker forecast 2024 revenues that were below consensus estimates, as the company attempts to chart a future for growth without blockbuster Covid...
...The stock is trading on 14 times forward earnings, on a par with Mattel. This seems overpriced given that Mattel has fared better sales-wise....
...The US government arranged with Pfizer to return 7.9mn Paxlovid courses at the end of 2023, at an estimated cost to the company of $4.2bn....
...Rival pharmaceutical groups are eager to enter the market, including AstraZeneca, which recently signed a licensing deal with Chinese company Eccogene for the rights to its weight loss pill....
...At one point pharmaceutical company Pfizer even set out a “no jerks” policy....
...The two recycling projects generate and sell plastic and carbon offset credits to big companies that use large amounts of plastic....
...Packaged food companies have built strong and trusted brands over decades....
...The Cypriot government allowed stocks to be used to treat cats suffering with another coronavirus in the Mediterranean country, though the company said it was not approved for veterinary treatment and no...
International Edition